Cited 0 times in
Helicobacter pylori 일,이차 제균요법 실패 후 Moxifloxacin 포함 삼제병합요법 시도
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2015-08-26T16:40:10Z | - |
dc.date.available | 2015-08-26T16:40:10Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/114880 | - |
dc.description.abstract | Background/Aims: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. Methods: The subjects consisted of 201 patients nfected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. Results:The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth riple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). Conclusions: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 111~117 | - |
dc.language | Korean Journal of Gastroenterology | - |
dc.publisher | Korean Journal of Gastroenterology | - |
dc.relation.isPartOf | Korean Journal of Gastroenterology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Helicobacter pylori | - |
dc.subject.MESH | Second-line therapy | - |
dc.subject.MESH | Rescue therapy | - |
dc.subject.MESH | Moxifloxacin | - |
dc.title | Helicobacter pylori 일,이차 제균요법 실패 후 Moxifloxacin 포함 삼제병합요법 시도 | - |
dc.title.alternative | Trial of Moxifloxacin-containing Triple Therapy after Initial and Second-line Treatment Failures for Helicobacter pylori Infection | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | 천재희 | - |
dc.contributor.googleauthor | 김나영 | - |
dc.contributor.googleauthor | 송인성 | - |
dc.contributor.googleauthor | 정현채 | - |
dc.contributor.googleauthor | 서승오 | - |
dc.contributor.googleauthor | 김정목 | - |
dc.contributor.googleauthor | 박영수 | - |
dc.contributor.googleauthor | 황진혁 | - |
dc.contributor.googleauthor | 김진욱 | - |
dc.contributor.googleauthor | 이동호 | - |
dc.identifier.doi | OAK-2005-02088 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J02015 | - |
dc.identifier.eissn | 2233-6869 | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | Second-line therapy | - |
dc.subject.keyword | Rescue therapy | - |
dc.subject.keyword | Moxifloxacin | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 111 | - |
dc.citation.endPage | 117 | - |
dc.identifier.bibliographicCitation | Korean Journal of Gastroenterology, Vol.45(2) : 111-117, 2005 | - |
dc.identifier.rimsid | 39284 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.